Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $11.08 to $12.29
• 50-Day Range: $9.80 to $12.02
• 52-Week Range: $9.71 to $16.00
• Volume: 251,793 shs
• Average Volume: 112,576 shs
• Market Capitalization: $289.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.25
• Consensus Rating: Buy

Artiva Biotherapeutics Stock Analysis - MarketRank™

Artiva Biotherapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 344th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Artiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Artiva Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($4.60) to ($2.70) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ARTV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artiva Biotherapeutics does not currently pay a dividend.

Dividend Growth

Artiva Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ARTV.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Artiva Biotherapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

MarketBeat Follows

3 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Artiva Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,999,976.00 in company stock and sold $0.00 in company stock.

ARTV Stock Analysis - Frequently Asked Questions

How have ARTV shares performed this year?

Artiva Biotherapeutics' stock was trading at $11.77 on January 1st, 2024. Since then, ARTV shares have increased by 1.1% and is now trading at $11.90.
View the best growth stocks for 2024 here.

How were Artiva Biotherapeutics' earnings last quarter?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) released its quarterly earnings data on Thursday, August, 29th. The company reported ($19.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by $18.03.

When did Artiva Biotherapeutics IPO?

Artiva Biotherapeutics (ARTV) raised $167 million in an IPO on Friday, July 19th 2024. The company issued 13,920,000 shares at $12.00 per share.

When did the company's quiet period expire?

Artiva Biotherapeutics' quiet period expired on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Artiva Biotherapeutics?

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/29/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 12/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CUSIP: N/A
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.25
• High Stock Price Target: $23.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +78.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $33.74 million
• Price / Sales: 8.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,290,000
• Free Float: N/A
• Market Cap: $289.05 million
• Optionable: N/A
• Beta: N/A